The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Mar. 28, 7:01 AM

Slide #10. ZS Pharma, Inc. Secondary Offering

Company: ZS Pharma, Inc. (NASDAQ:ZSPH)
Date announced: 3/23/2015
Shares Offered: 4,015,939
Date of Pricing: 3/25/2015
Price Per Share: $46.25
Secondary Offering Details: ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to market and other conditions 3,300,000 shares of its common stock in an underwritten public offering. A single selling stockholder, Alta Partners VIII, L.P., expects to grant the underwriters a 30-day option to purchase up to 495,000 additional shares of the Company's common stock. - updated 3/25 - ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,300,000 shares of common stock to 4,015,939 shares of common stock. The shares are being offered to the public at a price of $46.25 per share, resulting in aggregate proceeds to the Company of $185.7 million before underwriting discounts and expenses. In addition, a single selling stockholder, Alta Partners VIII, L.P., has granted the underwriters a 30-day option to purchase up to 602,390 additional shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 30, 2015, subject to customary closing conditions.

ZS Pharma is a biopharmaceutical company focused on the development and commercialization of an oral sorbent compound, zirconium silicate, which is a treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Co.'s zirconium silicate technology allows it to create ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. Co.'s ZS-9, treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium in the blood (greater than 5.0 mEq/L) increase the risk of muscle dysfunction.
Open the ZSPH Page at The Online Investor »

Company Name:  ZS Pharma Inc
Website:  www.zspharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ZSPH:  15
Total Market Value Held by ETFs:  $19.15M
Total Market Capitalization:  $878.00M
% of Market Cap. Held by ETFs:  2.18%
 

Open the ZSPH Page at The Online Investor (in a new window) »

March 28, 2015    7:01 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.